Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
about
Interventions to reduce weight gain in schizophreniaEvaluation of the clinical efficacy of asenapine in schizophreniaUnmet needs in the management of schizophreniaQuality of medical care for persons with serious mental illness: A comprehensive reviewMonitoring and managing metabolic effects of antipsychotics: a cluster randomized trial of an intervention combining evidence-based quality improvement and external facilitation.Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health CentreExcessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors.Modern antipsychotic drugs: a critical overviewEffectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review.Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.Pharmacovigilance on olanzapine.Physical performance and disability in schizophrenia.Treatment response to the RENEW weight loss intervention in schizophrenia: impact of intervention settingPhysical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Effect of initial ziprasidone dose on treatment outcome of korean patients with acute manic or mixed episodes.Change in framingham risk score in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, 6-week trial of ziprasidone and olanzapine.Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression.Beliefs and attitudes towards mental illness: an examination of the sex differences in mental health literacy in a community sample.Relationships between Brain Structure and Metabolic Changes in Schizophrenia Patients Treated with Olanzapine: A Voxel-Based Morphometric Study.Clozapine modifies the differentiation program of human adipocytes inducing browning.Association Study of Fat-mass and Obesity-associated Gene and Body Mass Index in Japanese Patients with Schizophrenia and Healthy Subjects.Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial.Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review.Association between the HTR2C rs1414334 C/G gene polymorphism and the development of the metabolic syndrome in patients treated with atypical antipsychotics.Metabolic syndrome in people with schizophrenia: a review.Brain stimulation in the treatment of late-life severe mental illness other than unipolar nonpsychotic depression.Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis.Lifestyle factors and the metabolic syndrome in Schizophrenia: a cross-sectional study.Twenty-year progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis.Smoking and Serum Lipid Profiles in Schizophrenia.Challenges for policy makers and organizational leaders: addressing trends in mental health inequalities.Managing physical and mental health conditions: Consumer perspectives on integrated care.Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis.What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?
P2860
Q24243093-EF4EDB18-95C2-47AE-AE21-98E98E22B201Q24630385-E494F101-4579-466C-BB66-4DC8FA9831CDQ26822917-2AECE46A-EDBA-45FB-9512-43C191A38769Q27026165-04EA0F0D-8159-4790-8FB5-0492A3162247Q30558767-261DA98B-FFD1-46B0-B68F-7126E6A9CCB4Q33236751-409116BF-7808-4189-818F-133B880ADFB6Q33256430-AFAE3361-79B5-499B-A43E-0FA9DD2EA068Q33663582-35A4BBCA-3FF0-4D8F-AD19-D657696E3B32Q33853390-5924FFB1-C577-4003-842E-60027393CC47Q33868229-F2919C78-FF26-4546-BAC6-4086E8D0C5BDQ34054063-F1044A08-8CC7-45DD-8DAE-025CF8B9CEBFQ34138231-D76CC246-1C32-40C6-B39A-4F37B1D0F68AQ34224072-58E14166-2DDB-473C-86DE-0C796AE8A7CBQ34619959-BB1486B8-4888-478F-B177-B2C52D40AA30Q34623350-1D6CCC93-F0D3-415F-949F-F79260006495Q35238333-977FE6AB-8ADE-43A4-B43D-41A352C274C4Q35574462-DE37A107-2C68-4FCB-9065-380CEABDC3F2Q35804713-1C710A63-261D-48FE-ACD1-4F2F90607257Q36089778-4D184877-4CCC-4034-A1CE-79794192203AQ36169521-4DD55D37-C128-476E-BEF2-A55CFC9EDE1DQ36206591-CCE0F647-5B6A-4A64-87DA-698B1D4EA345Q36600861-B397E584-9965-4926-B5B6-8C2FB4869740Q36714070-61CAE96B-B080-4A08-8B67-30E4CAB1C9C9Q36774139-D4F993C1-F626-4F82-BB81-11B6DD433031Q37047473-B47CE6AA-6406-4A79-B575-3F175618104AQ37087294-B95ECFA7-ACB9-4E48-A40E-116C2275825CQ37129646-3B3D64A1-4DC3-4349-93FF-BFC374C11F3DQ37510360-DC714FEC-2FF9-468A-BB45-AE742EB7F316Q37635208-C234CCD3-8DBD-4739-9830-2A162FC4086CQ37642973-CDEDCEA6-11B8-4954-9683-90193814F4BDQ38749110-8B81B2DB-A66B-450A-976C-5D7421D9F702Q40831671-05A84D8D-7BFF-493F-BC0C-AAC9C5029BA1Q41853522-CA35B84F-05DC-49D0-877B-FCADEBC51797Q47150681-51CAD0E5-18C2-448F-9246-779EAEFA41E7Q52755746-389324C9-BC49-47B1-844B-2A04E180BCD9Q55023835-3D45CBA5-3ADF-4234-8BFD-68204BFC471E
P2860
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Antipsychotic-induced weight g ...... n patients with schizophrenia.
@ast
Antipsychotic-induced weight g ...... n patients with schizophrenia.
@en
type
label
Antipsychotic-induced weight g ...... n patients with schizophrenia.
@ast
Antipsychotic-induced weight g ...... n patients with schizophrenia.
@en
prefLabel
Antipsychotic-induced weight g ...... n patients with schizophrenia.
@ast
Antipsychotic-induced weight g ...... n patients with schizophrenia.
@en
P2093
P1476
Antipsychotic-induced weight g ...... in patients with schizophrenia
@en
P2093
Charles H Hennekens
Dan W Haupt
Daniel E Casey
David C Henderson
Harold E Lebovitz
Jean-Pierre Lindenmayer
John W Newcomer
Mary Ann Banerji
Michael Davidson
Michael J Sernyak
P304
4-18; quiz 19-20
P478
65 Suppl 7
P577
2004-01-01T00:00:00Z